AN2 Therapeutics reports Q2 2022 cash of $115.8M, updates on epetraborole trials

AN2 Therapeutics, Inc.

2022-Q2 EPS reported -$1.74

Cash, cash equivalents and investments $115.8M at June 30, 2022; sufficient to fund operations through mid-2024.
Enrolling U.S. patients in Phase 2/3 trial of epetraborole for treatment-refractory MAC lung disease; topline Phase 2 results expected mid-2023.
Completed Phase 1 PK/safety study in Japan; gained PMDA alignment on microbiological primary endpoint for potential registration.
Maggie FitzPatrick appointed to Board of Directors; she previously led public affairs at Johnson & Johnson.
R&D and G&A expenses increased due to higher trial activity and expanded post-IPO operations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.